Agilent Technologies' (A) "Equal Weight" Rating Reiterated at Barclays

Key Points

• Barclays has reiterated an "equal weight" rating for Agilent Technologies (NYSE:A), maintaining a price target of $125.00, indicating a slight upside potential of 0.41% from its current price.
• Recent analyst activity includes both upgrades and target price adjustments, with a consensus rating of "Moderate Buy" and an average price target of $139.25.
• Agilent Technologies reported strong earnings, matching the consensus estimate at $1.37 per share and achieving revenue of $1.74 billion, surpassing analyst expectations.

Agilent Technologies (NYSE:A - Get Free Report)'s stock had its "equal weight" rating reissued by stock analysts at Barclays in a research note issued on Friday,Benzinga reports. They presently have a $125.00 price objective on the medical research company's stock. Barclays's price objective points to a potential downside of 0.17% from the stock's current price.

Several other research analysts have also issued reports on A. TD Cowen raised their target price on Agilent Technologies to $150.00 and gave the stock a "buy" rating in a research report on Thursday, May 29th. JPMorgan Chase & Co. lowered their price objective on Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating for the company in a research report on Thursday, May 29th. Leerink Partners lifted their price objective on Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research note on Friday, May 30th. UBS Group decreased their target price on shares of Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating for the company in a research report on Thursday, May 29th. Finally, Wall Street Zen upgraded shares of Agilent Technologies from a "hold" rating to a "buy" rating in a research report on Saturday, June 28th. Six equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $139.25.

Agilent Technologies Trading Down 0.4%

Shares of NYSE:A traded down $0.45 during midday trading on Friday, hitting $125.21. 2,412,746 shares of the stock were exchanged, compared to its average volume of 1,955,043. The business's 50-day moving average price is $118.57 and its 200 day moving average price is $116.30. Agilent Technologies has a 12 month low of $96.43 and a 12 month high of $153.84. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71 and a current ratio of 2.25. The stock has a market capitalization of $35.57 billion, a price-to-earnings ratio of 29.39, a P/E/G ratio of 3.91 and a beta of 1.24.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.37. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.67 billion. During the same quarter last year, the business earned $1.32 EPS. The firm's quarterly revenue was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Analysts predict that Agilent Technologies will post 5.58 earnings per share for the current year.

Insider Buying and Selling

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of Agilent Technologies stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total value of $177,099.52. Following the completion of the sale, the chief executive officer directly owned 37,448 shares of the company's stock, valued at approximately $4,397,893.12. The trade was a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Institutional Trading of Agilent Technologies

Several large investors have recently made changes to their positions in A. Orion Porfolio Solutions LLC boosted its holdings in Agilent Technologies by 20.8% in the second quarter. Orion Porfolio Solutions LLC now owns 11,784 shares of the medical research company's stock worth $1,391,000 after acquiring an additional 2,028 shares in the last quarter. MASTERINVEST Kapitalanlage GmbH bought a new stake in shares of Agilent Technologies during the second quarter valued at approximately $1,805,000. B. Riley Wealth Advisors Inc. acquired a new position in shares of Agilent Technologies during the second quarter worth approximately $305,000. Marex Group plc bought a new position in shares of Agilent Technologies in the 2nd quarter worth $580,000. Finally, State of Wyoming bought a new position in shares of Agilent Technologies in the 2nd quarter worth $35,000.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.